香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 GUSHENGTANG HOLDINGS LIMITED 固 生 堂 控 股 有 限 公 司 （根據開曼群島法律註冊成立的有限公司） （股份代號：2273） 自願性公告 根據購回授權購回股份 根據股東於2025年6月20日舉行的股東週年大會上通過的股東決議案，本公司 董事（「董事」）獲授購回最多23,696,549股本公司股份（「股份」）的一般授權，佔 截至2025年6月20日已發行股份總數的10%（「購回授權」）。 於2025年8月29日，董事會（「董事會」）決議行使購回授權，適時於公開市場購 回股份，總價最多300百萬港元（「先前建議股份購回」）。除先前建議股份購回 總價，於2025年11月6日，董事會決議進一步行使購回授權，適時於公開市場 購回股份，再次增加最多300百萬港元（「建議股份購回」）。建議股份購回於本 公告日期開始，直至下列最早者：(i)本公司下屆股東週年大會結束時，(ii)任何 適用 ...

固生堂(02273)发布公告，于2025年11月6日，该公司斥资约1376.99万港元购回49.35万股股份，每股回 购价27.74-28.2港元。 ...

Core Viewpoint - The company, Gushengtang (02273), announced a share buyback plan, indicating a strategic move to enhance shareholder value through repurchasing shares at a price range of 27.74 to 28.2 HKD per share [1] Group 1 - The company will spend approximately 13.7699 million HKD to repurchase 493,500 shares [1]

格隆汇11月6日丨固生堂(02273.HK)发布公告，2025年11月6日耗资1376.99万港元回购49.35万股，回购 价格每股27.74-28.2港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年11月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02273 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Core Viewpoint - Company maintains net profit forecasts for 2025-2026 at RMB 4.05 billion and RMB 5.21 billion, with current stock price corresponding to P/E ratios of 14.8 and 11.3 for 2025-2026, respectively, and a target price of HKD 45.8, indicating a potential upside of 62.5% [1] Group 1: Financial Performance - In Q3 2025, the number of patients treated reached approximately 1.607 million, representing a year-on-year growth of 8.2% [2] - The company expects the average selling price (ASP) to stabilize, despite minor impacts from recent healthcare policy changes, with profit margins anticipated to continue improving due to cost optimization efforts [2] Group 2: Strategic Initiatives - The company has partnered with a digital healthcare platform in Singapore to integrate traditional Chinese medicine (TCM) services into Western medical clinics, aiming for a 70% control in the TCM treatment area [3] - The "National Medicine AI Avatar" platform was launched in Singapore, providing a learning platform for TCM practitioners and laying the groundwork for global resource sharing [3] Group 3: Shareholder Returns - From Q1 to Q3 2025, the company repurchased shares worth RMB 141 million and declared a mid-term dividend of RMB 76 million, resulting in a total shareholder return of approximately RMB 217 million, equating to a return rate of 3.2% [4] - With the recent share buyback announcement, the expected shareholder return rate could rise to 5.2%, with a potential annual return rate of around 7% if the dividend distribution remains consistent [4]

Core Viewpoint - Company maintains net profit forecasts for 2025-2026 at RMB 4.05 billion and RMB 5.21 billion, with current stock price corresponding to P/E ratios of 14.8 and 11.3 for those years, respectively. The target price is set at HKD 45.8, indicating a potential upside of 62.5% from the current level [1] Group 1: Financial Performance - In Q3 2025, the number of patients treated reached approximately 1.607 million, reflecting a year-on-year growth of 8.2% [2] - The company expects the average selling price (ASP) to stabilize, despite minor impacts from recent healthcare policy changes. The profit margin is anticipated to continue improving due to cost optimization efforts [2] Group 2: Strategic Initiatives - The company has partnered with a digital healthcare platform in Singapore to integrate traditional Chinese medicine (TCM) services into Western medical clinics, aiming for a 70% control in the TCM treatment area [3] - The "National Medicine AI Avatar" platform was launched in Singapore, providing a learning platform for TCM practitioners and laying the groundwork for global resource sharing [3] Group 3: Shareholder Returns - From Q1 to Q3 2025, the company repurchased shares worth RMB 141 million and declared a mid-term dividend of RMB 76 million, resulting in a total shareholder return of approximately RMB 217 million, equating to a return rate of 3.2% [4] - With the recent share buyback announcement, the expected shareholder return rate could rise to 5.2%, with a potential annual return rate of around 7% if the dividend distribution remains consistent [4]

Core Points - The company, Gushengtang, announced a share buyback on November 5, purchasing 467,800 shares at prices ranging from HKD 28.080 to HKD 28.620, totaling HKD 13.2576 million [1] - Since September 10, the company has conducted buybacks for 38 consecutive days, acquiring a total of 7.3545 million shares for a cumulative amount of HKD 223 million, during which the stock price has decreased by 15.35% [1] - Year-to-date, the company has executed 61 buybacks, totaling 10.3091 million shares and an aggregate buyback amount of HKD 318 million [1] Buyback Details - On November 5, the company bought back 46.78 thousand shares at a maximum price of HKD 28.620 and a minimum price of HKD 28.080, with a total expenditure of HKD 13.2576 million [2] - The buyback activity reflects a strategic move to support the stock price amid a decline, as evidenced by the cumulative drop of 15.35% during the buyback period [1]

Core Viewpoint - The company, Guoshengtang (02273.HK), has demonstrated resilience in the face of consumer pressure, showcasing steady growth as a leader in traditional Chinese medical services [1] Group 1: Share Buyback - On November 5, 2025, Guoshengtang announced a share buyback, spending HKD 13.2576 million to repurchase 467,800 shares [1] - The buyback price ranged from HKD 28.08 to HKD 28.62 per share [1] Group 2: Company Performance - Guoshengtang is positioned as a leader in the traditional Chinese medical services sector, highlighting its robust growth despite challenging consumer conditions [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年11月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02273 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事 ...